ACTengine IMA203 & IMA203CD8 TCR-T Cell Therapy Targeting PRAME in Solid Tumor Patients
Time: 8:30 am
day: Day 1
Details:
• Phase 1b clinical data on IMA203 demonstrate deep and durable responses in heavily pretreated metastatic melanoma patients at RP2D
• Next-generation IMA203CD8 Phase 1a dose escalation data show enhanced pharmacology and potency per cell; to be evaluated for future in development in solid cancers with medium-level PRAME copy numbers
• SUPRAME, randomized-controlled Phase 3 trial to evaluate IMA203 in 2L+ metastatic melanoma patients, initiated in December 2024
